Aaron Ambrad, MD

Radiation Oncologist

Breast

Gastrointestinal Malignancies

Genitourinary

Head & Neck

Lung

Skin & Sarcoma

"His knowledge and expertise, treatment plans and follow ups, not to mention the exceptional bedside manner and genuinely caring about you are the reason I am here today. I was blessed with having this man as my doctor and would recommend him to anyone and everyone!"

Dr. Aaron Ambrad is a highly esteemed, board-certified Radiation Oncologist who has been a vital part of Ironwood Cancer & Research Centers for nearly 20 years. He is a first-generation Colombian American and is the 13^th of 15 doctors in his family.

Dr. Ambrad earned his medical degree from the University of Illinois College of Medicine. He then completed his residency in Radiation Oncology at the University of Arizona Health Sciences Center in 2004, where he distinguished himself as Chief Resident. Dr. Ambrad utilizes the latest advanced technologies such as Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT), and stereotactic radiation (SBRT) with a particular focus on treating breast, prostate, lung, head and neck, gastrointestinal (GI), and skin cancers. Dr. Ambrad brings extensive expertise to his practice and the oncology community. He has made significant contributions to brain cancer research, with several publications to his credit. Additionally, he is actively involved in multiple clinical trials and serves as a mentor for medical students.

Dr. Ambrad is highly regarded by his patients for his dedication and compassionate bedside manner. He has been recognized with a 10-year excellence award by Phoenix Magazine, having been named a “Top Doc” in 2012, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, and 2025.

Present Title & Subspecialties

Title

Radiation Oncology

Subspecialties

BreastGastrointestinal MalignanciesGenitourinaryHead & NeckLungSkin & Sarcoma

Education & Training

Medical School

University of Illinois College of Medicine

Fellowships

University of Arizona Health Sciences Center Radiation Oncology

Cancers Treated

Certifications & Professional Memberships

Board Certified in Radiation Oncology
ASTRO
ARRO
ASCO

Publications

Patel J., Glanzberg H., Stadheim C., Ambrad A.A., and Meuillet E.J. DPIEL, a novel Akt inhibitor radiosensetizes glioblastoma cells, independently of PTEN expression. Submitted to Can Res.

Brandis A., Patel J., Stadheim C., Ambrad A.A., Martinez J.D., and Meuillet E.J. Unraveling the role of CDK6 in the radiosensitization of glioblastoma cells. Submitted to Oncogene.

Stea B., Falsey R., Kislin K., Patel J., Glanzberg H., Carey S., Ambrad, A.A., Meuillet E.J. and Martinez J.D. Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 (‘Iressa’) Can Lett, 2003, Dec 8; 202(1): 43-51.

Ambrad A.A., Stadheim C., Kislin K., Stea B., Martinez J.D. and Meuillet E.J. The Radiosensitization of the Human Glioblastoma Multiforme Cell Line U251 by the EGFR Inhibitor ZD1839 (‘Iressa’) is not due to the inhibition of the MEK1/ERK-1/2 Pathway. Mol Can Res.

Glanzberg H., Kislin K., Stadheim C., Ambrad A.A., Stea B., Martinez J.D. and Meuillet E.J. Geldanamycin and 17-AAG Radiosensitize Human Glioblastoma Cells, Mol Can Res.

Kislin K., Glanzberg H., Stadheim C., Ambrad A.A., Falsey R., Stea B., Martinez J.D. and Meuillet E.J. Inhibition of Heat Shock Protein Hsp90 by the Geldanamycin Derivative 17-allylamino-17-demethoxygeldanamycin (17-AAG) Radiosensitizes Glioblastoma Multiforme. AACR, Washington, D.C. July 11-14, 2003

Stea B., Kislin K., Stadheim C., Ambrad A.A., Falsey R., Meuillet E.J. and Martinez J.D. ZD1839 (“Iressa”) Radiosensitizes Glioblastoma Multiforme by Altering Patterns of Genes Expression in a Time Dependent Manner. AACR, Washington, D.C. July 11-14, 2003

Ambrad A.A., Stea B., Martinez J., Falsey R., Kislin K., and Meuillet E.J. Mechanism of the Radiosensitization of Glioblastoma Multiforme by the EGFR Tyrosine Kinase Inhibitor, ZD1839 (‘Iressa’). Society of Neuro-Oncology Meeting, San Diego, CA. Nov. 21-24, 2002

Ambrad A.A., Stea B., Martinez J., Mahadevan D., Falsey R., Kislin K., and Meuillet E.J. ZD1839 (‘Iressa’) an EGFR Tyrosine Kinase Inhibitor Radiosensitizes Glioblastoma Multiforme by Inhibition of a Cell Survival Pathway. 44^th Annual ASTRO Meeting, New Orleans, LA. October 5-10, 2002

Kenneth M. Algazy, Mitchell Machtay, Joseph S. Friedberg, Aaron Ambrad, Stephen M. Hahn, David I. Rosenthal, James P. Stevenson, Joseph Treat, Eli Glatstein, Larry R. Kaiser: Neoadjuvant Chemoradiotherapy Prior to Surgery for Stage IIIA Non-Small Cell Lung Carcinoma (NSCLC): A Nonrandomized Comparison of Carboplatin/Paclitaxel to Etoposide/Cisplatin. 35^th Annual ASCO Meeting, Atlanta, GA. May 15-18, 1999

Krisch R.E., Ayene S.I., Ambrad A.A., Koch C.J.: Mechanisms of double-strand break formation by secondary glycerol radicals in irradiated SV40 DNA. 10^th International Congress of Radiation Research, Wurzburg, Germany. Aug. 27-Sept. 1, 1995

Ayene S.I., Koch C.J., Ambrad A.A., Krisch R.E.: Modification of oxygen effect on DNA strand break formation by scavenging environment. 42^nd Annual Meeting of the Radiation Research Society, Nashville, TN. April 29-May 4, 1994

Ayene S.I., Koch C.J., Ambrad A.A., Krisch R.E.: Interaction of thiol and non-thiol scavengers in the modification of radiation-induced DNA damage. 18^th LH Gray Conference, University of Bath, England. April 10-14, 1994

Honors & Awards

PHOENIX Magazine Top Doc Award 2012, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, and 2025.

Intern of the Year, 1999 to 2000, UPMC-McKeesport

CV

https://www.ironwoodcrc.com/wp-content/uploads/2019/02/Ambrad-CV-Updated.pdf

Videos

Videos

Languages

Location

Scottsdale

8880 E. Desert Cove Ave.

Scottsdale, AZ 85260

Hours:

Monday-Friday

8am-5pm

Contact

480-257-1997

Reviews for Aaron Ambrad, MD